VolitionRx walks into today's Q1 2026 print with a dramatically altered short-seller landscape — one where a massive cover-down has reshaped the positioning story entirely.
The most striking shift is in short interest. Bears cut their exposure by roughly 94% over the past week, with estimated shares short collapsing from nearly 5.9 million to just 371,000. Short interest now sits at only 0.30% of the free float — negligible by any measure. The ORTEX short score dropped sharply in response, falling from ~90 down to 63. That's a significant reset: a score near 90 signals extreme short-selling pressure; 63 is elevated but no longer alarm-level. Cost to borrow remains firm at 23%, suggesting the lending market is not yet fully relaxed, but the sharp withdrawal of short positions tells the cleaner story.
Options positioning has flipped in a way that supports the narrative of retreating bears. The put/call ratio has tumbled to 0.41, well below its 20-day average of 1.06 — a reading that, one month ago, swung as high as 5.0 at the 52-week peak. That extreme was the sign of maximum defensiveness. Today's reading is the opposite: calls dominate, and options flow looks unusually bullish relative to recent history. Whether that represents genuine conviction or simply the unwinding of hedges tied to the prior short position is the question the print will help answer.
The historical reaction pattern offers limited comfort for bulls. The last two confirmed quarterly results both delivered day-one declines in the range of 15%. The most recent Q1 report in April triggered a 15% one-day drop and an additional 13% erosion over the following five trading days. A pre-earnings announcement in March briefly produced a 5% gain before reversing to an 11% five-day loss. The pattern, across all three episodes, ends in the red. Tonight's news already offers one data point: Q1 EPS came in at -$0.97, missing the -$0.75 estimate, though revenue of $985K meaningfully beat the $427K estimate. Sales include progress from the Nu.Q cancer diagnostics pipeline, including a recent clinical manuscript submission for the feline lymphoma assay — a niche but tangible commercial milestone.
The print, then, tests whether a revenue beat can offset a significant EPS miss at a company with an $18.7 million market cap, no analyst consensus target, and a borrow market still reflecting residual wariness at 23% cost. The absence of institutional depth — just 45 holders on record — means thin ownership amplifies any price move in either direction.
See the live data behind this article on ORTEX.
Open VNRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
